SwePub
Sök i LIBRIS databas

  Extended search

L773:0957 5235 OR L773:1473 5733
 

Search: L773:0957 5235 OR L773:1473 5733 > (2000-2004) > Prevention of venou...

  • Alikhan, R (author)

Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study

  • Article/chapterEnglish2003

Publisher, publication year, extent ...

  • 2003

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:e4b653eb-a74e-4ab2-90a2-44bb8f7c55ba
  • https://lup.lub.lu.se/record/309407URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • The Medical Patients with Enoxaparin (MEDENOX) trial was a randomized, placebo-controlled study that defined the risk of venous thromboembolism (VTE) in acutely ill, immobilized, general medical patients and the efficacy of the low-molecular-weight heparin, enoxaparin, in preventing thrombosis. We performed a post-hoc analysis to evaluate the effect of 40 mg enoxaparin once daily on MEDENOX patient outcome in different types of acute medical illness (heart failure, respiratory failure, infection, rheumatic disorder and inflammatory bowel disease) and pre-defined risk factors (chronic heart and chronic respiratory failure, age, immobility, previous VTE and cancer). The primary outcome was the occurrence of documented VTE between days 1 and 14. The relative risk reduction [95% confidence intervals (CI)] for VTE comparing 40 mg enoxaparin with placebo in the subgroups were: acute heart failure, 0.29 (95% CI, 0.10-0.84); acute respiratory failure, 0.25 (95% CI, 0.10-0.65); acute infectious disease, 0.28 (95% CI, 0.09-0.81); and acute rheumatic disorder, 0.48 (95% CI, 0.11-2.16). The relative risk reduction for VTE in the pre-defined risk factor subgroups were: chronic heart failure, 0.26 (95% Cl, 0.08-0.92); chronic respiratory failure, 0.26 (95% CI, 0.10-0.68); age, 0.22 (95% CI, 0.09-0.51); immobility, 0.53 (95% CI, 0.14-1.72); previous VTE, 0.49 (95% CI, 0.15-1.68); and cancer, 0.50 (95% CI, 0.14-1.72). The beneficial effects of enoxaparin extend to a wide range of acutely ill medical patients. (C) 2003 Lippincott Williams Wilkins.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Cohen, AT (author)
  • Combe, S (author)
  • Samama, MM (author)
  • Desjardins, L (author)
  • Eldor, A (author)
  • Janbon, C (author)
  • Leizorovicz, A (author)
  • Olsson, Carl-GustavLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine(Swepub:lu)extLU-70 (author)
  • Turpie, AGG (author)
  • Institutionen för kliniska vetenskaper, MalmöMedicinska fakulteten (creator_code:org_t)

Related titles

  • In:Blood Coagulation and Fibrinolysis14:4, s. 341-3461473-5733

Internet link

Find in a library

To the university's database

Find more in SwePub

By the author/editor
Alikhan, R
Cohen, AT
Combe, S
Samama, MM
Desjardins, L
Eldor, A
show more...
Janbon, C
Leizorovicz, A
Olsson, Carl-Gus ...
Turpie, AGG
show less...
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Hematology
Articles in the publication
Blood Coagulatio ...
By the university
Lund University

Search outside SwePub

Wikipedia about the author:
R_Alikhan
Alikhan, R
en

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view